0001493152-22-008102.txt : 20220330 0001493152-22-008102.hdr.sgml : 20220330 20220330084604 ACCESSION NUMBER: 0001493152-22-008102 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220330 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220330 DATE AS OF CHANGE: 20220330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 22783400 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000868278 false 0000868278 2022-03-30 2022-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): March 30, 2022

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   000-21617   23-2577138

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

711 Stewart Avenue, Suite 200

Garden City, New York

   11530
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 345-0919

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 30, 2022, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.01 Regulation FD.

 

As previously announced, the Company will conduct a conference call today, Wednesday, March 30, 2022, at 11:00 a.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments.

 

The information included in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.   Description
     
99.1   Press Release dated March 30, 2022
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Monica Brady
    Monica Brady
    Chief Financial Officer

 

Date: March 30, 2022

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

ProPhase Labs Announces Record Financial Results

for the Fourth Quarter and Full Year Ended December 31, 2021

 

Record Financial Results also expected for Q1 2022

 

Company to hold a conference call March 30, 2022, at 11:00AM ET

 

Garden City, NY – March 30, 2022 (GLOBE NEWSWIRE) – ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2021.

 

Financial highlights for the full year ended December 31, 2021, include the following:

 

  ● Net revenue of $79.0 million for the year ended December 31, 2021, as compared to $14.5 million for the year ended December 31, 2020, an increase of approximately 445%.
     
  ● Net Income of $6.3 million, or $0.41 per share, for the year ended December 31, 2022, as compared to a net loss of $2.1 million, or $(0.18) per share, for the year ended December 31, 2020.
     
  ● Adjusted EBITDA income of $18.1 million for the year ended December 31, 2021, as compared to adjusted EBITDA loss of $0.3 million for the year ended December 31, 2020.
     
  ● Cash, cash equivalents and marketable equity securities of $17.4 million and net working capital of $45.8 million at December 31, 2021.
     
  ● 580,000 diagnostics tests were performed in Fiscal 2021 including 350,000 diagnostics tests that were performed in the quarter ended December 31, 2021.

 

 

 

 

 

Financial highlights for the fourth quarter 2021 include the following:

 

  ● Net revenues of $45.2 million for the three months ended December 31, 2021, as compared to net revenues of $5.2 million for the three months ended December 31, 2020.
     
  ● Net income of $10.6 million, or $0.68 per share for the three months ended December 31, 2021, compared to a net loss of $1.0 million, or ($0.09) per share, for the three months ended December 31, 2020. This includes the impairment of a note receivable of $3.75 million.
     
  ● Adjusted EBITDA income of $16.5 million for Q4 2021 as compared to adjusted EBITDA income of $0.1 million for Q4 2020.
     
  ● 18.3% increase in gross margins to 54.5% for the three months ended December 31, 2021 as compared to 36.2% for the three months ended December 31, 2020.

 

Corporate highlights for the year ended December 31, 2021, and subsequently include the following:

 

  ● Built from scratch a 25,000 square foot state-of-the-art New York CLIA certified laboratory in Garden City, New York, corporate headquarters subsequently moved to this location.
     
  ● Second half of 2021, built strong leadership team with key promotions and additions to management team contributing to significant growth and improved operating efficiencies.
     
  ● Acquired Nebula Genomics, Inc., (“Nebula Genomics”) a privately owned personal genomics company, for an aggregate purchase price of $14.6 million. Nebula Genomics co-founder and renowned Harvard scientist, George Church, Ph.D., to spearhead ProPhase Labs new scientific advisory board.
     
  ● Presented at five investor conferences, including LD Micro, Benzinga Health Care Small Cap, H.C. Wainwright Global, SNN Network Summer, and the Q3 Investor Summit.
     
  ● Repurchased 166,824 shares at an aggregate amount of $944,000 or $5.66 per share, pursuant to ProPhase Labs previously announced repurchase program.
     
  ● Paid a special cash dividend of $0.30 per share on June 3, 2021. Subsequent to year end 2021, paid an additional special cash dividend of $0.30 per share on March 10, 2022.

 

 

 

 

 

Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “I am so proud of our entire team for the phenomenal success that we achieved in our first full year in the CLIA lab diagnostics testing business. Our testing levels increased significantly during Q4, due to our extensive expansion and diversification of our customer base, including independent pharmacies, schools, concierge services in multiple states, municipal contract wins, etc. At the same time, we now employ significantly more temporary employees which provide flexibility to increase and decrease the work force more efficiently as demand for testing fluctuates. Our strong Q4 financial results reflect this growth in customers combined with more efficient operations.

 

We expect Q1 2022 to produce even stronger results than Q4 2021. In addition to a high level of testing during the current quarter, and a more efficient work force, we have achieved additional efficiencies in laboratory processing which should increase gross margins even further. Furthermore, Q4 2021 included an impairment charge of $3.7 million that will not occur in Q1 2022. We therefore project record financial results for Q1 2022, which should include increases in working capital and cash levels for the quarter ending March 31, 2022, even after adjusting for the special dividend paid on March 10, 2022.

 

We expect waves of COVID-19 to continue, and are currently planning for an increase in the incidence of COVID-19 due to the BA2 variant which is currently accelerating in the UK. We are very well positioned for future waves. At the same time, within the next few months, we are planning to expand our clinical laboratory in Garden City, NY to provide additional diagnostic testing beyond COVID-19 related tests to leverage our existing and growing customer base.

 

We are proceeding as planned with our integration of Nebula Genomics into our ProPhase Precision Medicine division. We are confident that combining Nebula Genomics’ comprehensive genomic testing with our CLIA-certified lab capabilities will lead to faster turnaround times and lower price points, driving additional demand. We also plan to offer low-pass genomic testing at significantly lower price points. This will allow us to leverage our distribution network of more than 40,000 food, drug, and mass retail stores to further expand direct-to-consumer and big-box retail distribution of Nebula’s genomic sequencing products and services. Additional goals include the development of partnerships for Nebula’s proprietary library, research collaborations with universities, leveraging the Nebula data base, etc. Each of these initiatives could significantly grow sales as we look forward to 2022 and beyond.

 

We also anticipate year over year growth in 2022 in both our traditional dietary supplements and contract manufacturing businesses.

 

We will also continue to evaluate and pursue additional strategic and synergistic acquisitions to build our precision medicine and genomics research capabilities with the help of world-renowned genomics expert, George Church, co-founder of Nebula Genomics and advisor to ProPhase Labs,” concluded Mr. Karkus.

 

 

 

 

 

Financial Results

 

Year Ended December 31, 2021

 

Net revenue for Fiscal 2021 increased $64.5 million to $79.0 million, or 445% as compared to $14.5 million for Fiscal 2020. The increase in net revenue was the result of a $67.2 million increase in net revenue from diagnostic services, offset by a $2.7 million decrease in net revenue from consumer products. Fiscal 2021 had a full year of operations of diagnostic services, as compared to one month of operations in Fiscal 2020. The decrease in net revenue from consumer products for Fiscal 2021 as compared to Fiscal 2020 was primarily due to a decrease in the volume of customer orders as a result of the demand and inventory levels of third-party contract manufacturing customers, which was partially offset by $2.2 million of net revenue from the operations of Nebula.

 

Cost of revenues for Fiscal 2021 were $37.1 million, comprised of $29.4 million for diagnostic services and $7.6 million for consumer products. Cost of revenues for Fiscal 2020 were $9.9 million comprised of $0.6 million for diagnostic services and $9.3 million of consumer products. We realized a gross profit $42.0 million for Fiscal 2021 as compared to $4.6 million for Fiscal 2020. The increase of $37.4 million was comprised of an increase of $38.5 million in diagnostic services, offset by a $1.1 million decrease in consumer products. For Fiscal 2021, our gross margin was 53.1% as compared to 31.7% for Fiscal 2020. The increase in gross margin for Fiscal 2021 as compared to Fiscal 2020 is principally due to margins generally associated with our new diagnostic services business. Gross margins have historically been influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs and timing of shipments to customers.

 

Diagnostic expenses for Fiscal 2021 were $9.2 million as compared to $0.4 million of diagnostic expenses for Fiscal 2020. The increase in diagnostic expenses of $8.8 million was comprised of network providers expenses associated with our new diagnostic services business.

 

General and administration expenses increased $15.0 million for Fiscal 2021 to $22.5 million as compared to $7.5 million for Fiscal 2020. The increase in general and administration expenses for Fiscal 2021 as compared to Fiscal 2020 was principally growth in personnel expenses and professional fees associated with our new diagnostic services business.

 

Research and development costs for Fiscal 2021 and 2020 were $0.5 million and $0.6 million, respectively. The decrease in research and development costs was principally due to lower professional expenses.

 

As a result of the effects of the above, the net income from continuing operations before income taxes for Fiscal 2021 was $6.3 million as compared to a net loss from continuing operations of $2.3 million.

 

 

 

 

 

Our aggregate cash and cash equivalents and restricted cash as of December 31, 2021 were $8.7 million as compared to $6.8 million at December 31, 2020. Our working capital was $45.8 million and $9.6 million as of December 31, 2021 and 2020, respectively. The increase of $1.9 million in our cash and cash equivalents for the year ended December 31, 2021 was principally due to our receipt of aggregate net proceeds of $40.6 million from the issuance of common stock and warrants in a registered direct offering and subsequent public offering, proceeds from the sale of marketable debt securities of $15.9 million, and repayment of promissory note receivable of $0.3 million, offset by (i) purchases of marketable securities of $21.5 million, (ii) cash dividend payments of $4.5 million, (iii) issuance of a secured promissory note receivable of $1.0 million, (iv) payment of $9.1 million related to business acquisition, (v) repurchase of common shares for $0.9 million, (vi) capital expenditures of $4.2 million, and (vii) cash used in operations of $13.6 million.

 

Conference Call and Webcast Details

 

Management will host a conference call at 11:00 AM ET today, March 30, 2022, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10164499/f1e84ec36b

 

Please note that registered participants will receive their dial in number upon registration and may dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into ProPhase Lab’s call.

 

The conference call will be broadcast live and available for replay at https://services.choruscall.com/mediaframe/webcast.html?webcastid=XR6Twsmq and via the investor relations section of the Company’s website at www.ProPhaseLabs.com.

 

A webcast replay of the call will be available approximately two hours after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code #6560008.

 

 

 

 

 

About ProPhase Labs

 

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a diversified diagnostics and genomics company.

 

ProPhase Diagnostics, Inc., a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

 

ProPhase Precision Medicine, Inc., a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

 

ProPhase Global Healthcare, Inc., a subsidiary of ProPhase, was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

 

ProPhase has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Phamaloz contract manufacturing subsidiary.

 

ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

 

 

 

 

 

Forward Looking Statements

 

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including statements regarding our expectations with respect to Q1 2022 COVID-19 testing revenues and financial results, our plans to expand our diagnostic testing services, our ability to provide genomic testing with faster turnaround times and lower price points resulting in increased demand, our ability to leverage our distribution network to expand direct-to-consumer and big-box retail distribution of Nebula’s genomic sequencing products and services, our goals related to the development of partnerships and research collaborations, and our ongoing efforts to evaluate and pursue additional strategic and synergistic acquisitions to build our precision medicine and genomics research capabilities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to general economic conditions, the scale, scope and duration of the COVID-19 pandemic, consumer demand for our COVID-19 testing and other lab processing services, our ability to collect payment for the diagnostic tests we deliver, including our ability to collect payment from uninsured individuals if emergency funding is not allocated to the HRSA uninsured program, challenges relating to entering into new business lines, the competitive environment, our failure to obtain and maintain necessary regulatory approvals, our ability to continue to ramp up our labs’ testing capacity and execute on our business plan, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings.

 

Media Relations and Institutional Investor Contact:

 

ProPhase Labs, Inc.

267-880-1111

investorrelations@prophaselabs.com

 

Retail Investor Relations Contact:

 

Renmark Financial Communications

John Boidman

514-939-3989

Jboidman@renmarkfinancial.com

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

   December 31,   December 31, 
   2021   2020 
ASSETS          
Current assets          
Cash and cash equivalents  $8,408   $6,816 
Restricted cash   250    - 
Marketable debt securities, available for sale   8,779    1,639 
Marketable equity securities, at fair value   76    - 
Accounts receivable, net   37,708    3,155 
Inventory, net   4,600    3,039 
Prepaid expenses and other current assets   1,496    1,238 
Total current assets   61,317    15,887 
           
Property, plant and equipment, net   5,947    3,578 
Secured promissory note receivable   -    2,750 
Prepaid expenses, net of current portion   460    2,084 
Right-of-use asset, net   4,402    4,731 
Intangible assets, net   10,852    1,234 
Goodwill   5,709    901 
Other assets   608    240 
TOTAL ASSETS  $89,295   $31,405 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $7,026   $3,771 
Accrued diagnostic services   1,890    - 
Accrued advertising and other allowances   104    463 
Lease liabilities   663    329 
Deferred revenue   2,034    169 
Other current liabilities   3,807    1,562 
Total current liabilities   15,524    6,294 
           
Non-current liabilities:          
Deferred revenue, net of current portion   905    162 
Note payable   44    - 
Unsecured convertible promissory notes, net   9,996    9,991 
Lease liabilities, net of current portion   4,198    4,402 
Total non-current liabilities   15,143    14,555 
Total liabilities   30,667    20,849 
           
COMMITMENTS AND CONTINGENCIES          
           
Stockholders’ equity          
Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding   -    - 
Common stock authorized 50,000,000, $0.0005 par value, 15,485,900 and 11,604,253 shares outstanding, respectively   16    14 
Additional paid-in capital   104,552    61,674 
Retained earnings (accumulated deficit)   2,642    (3,631)
Treasury stock, at cost, 16,818,846 and 16,652,022 shares, respectively   (48,407)   (47,490)
Accumulated other comprehensive loss   (175)   (11)
Total stockholders’ equity   58,628    10,556 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $89,295   $31,405 

 

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands, except per share amounts)

(unaudited)

 

   For the years ended 
   December 31, 2021   December 31, 2020 
Revenues, net  $79,042   $14,514 
Cost of revenues   37,054    9,908 
Gross profit   41,988    4,606 
           
Operating expenses:          
Diagnostic expenses   9,174    448 
General and administration   22,493    7,498 
Research and development   520    633 
Total operating expenses   32,187    8,579 
Gain on sale of real estate   -    1,892 
Income (loss) from operations   9,801    (2,081)
           
Interest income, net   642    62 
Interest expense   (1,148)   (295)
Change in fair value of investment securities   (240)   - 
Impairment of secured promissory note receivable   (3,750)   - 
Income (loss) from continuing operations before income taxes   5,305    (2,314)
Income tax benefit (expense)   968    (12)
Income (loss) from continuing operations after income taxes   6,273    (2,326)
           
Discontinued Operations:          
Income from discontinued operations   -    201 
Net income (loss)  $6,273   $(2,125)
           
Other comprehensive loss:          
Unrealized loss on marketable debt securities   (164)   (9)
Total comprehensive income (loss)  $6,109   $(2,134)
           
Basic and earnings (loss) per share:          
Income (loss) from continuing operations  $0.41   $(0.20)
Income from discontinued operations   -    0.02 
Net income (loss) per share  $0.41   $(0.18)
           
Diluted earnings (loss) per share:          
Income (loss) from continuing operations  $0.40   $(0.20)
Income from discontinued operations   -    0.02 
Net income (loss) per share  $0.40   $(0.18)
           
Weighted average common shares outstanding:          
Basic   15,172    11,595 
Diluted   18,393    11,595 

 

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

   For the years ended 
   December 31, 2021   December 31, 2020 
Cash flows from operating activities          
Net income (loss)  $6,273   $(2,125)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Realized (gain) loss on marketable debt securities   165    (2)
Gain on discontinued operations, net of taxes   -    (201)
Depreciation and amortization   3,234    449 
Amortization of debt discount   5    1 
Amortization on right-of-use assets   329    9 
Lower of cost or net realizable value inventory adjustment   -    68 
Consulting expense paid through reduction of secured promissory note receivable   -    250 
Impairment of secured promissory note receivable   3,750    - 
Stock-based compensation expense   3,183    1,459 
Change in fair value of investment securities   240    - 
Non-cash interest income on secured promissory note receivable   (316)   - 
Gain on sale of real estate   -    (1,892)
Accounts receivable allowances   (3,865)   97 
Inventory valuation reserve   267    (193)
Changes in operating assets and liabilities:          
Accounts receivable   (30,466)   (1,136)
Inventory   (1,746)   (1,275)
Prepaid and other assets   1,445    (3,005)
Other assets   (368)   (240)
Accounts payable and accrued expenses   2,450    3,339 
Accrued diagnostic services   1,890    - 
Deferred revenue   2,608    - 
Lease liabilities   130    (9)
Other liabilities   (2,827)   1,814 
Net cash used in operating activities   (13,619)   (2,592)
           
Cash flows from investing activities          
Business acquisitions, net of cash acquired   (9,066)   - 
Issuance of secured promissory note receivable   (1,000)   (3,000)
Purchase of marketable securities   (21,527)   (4,560)
Proceeds from sale of marketable debt securities   15,858    3,840 
Repayment of promissory note   300    - 
Escrow receivable   -    4,812 
Acquisition of Confucius Labs   -    (2,500)
Proceeds from sale of building, net   -    2,081 
Capital expenditures   (4,231)   (1,689)
Net cash used in investing activities   (19,666)   (1,016)
           
Cash flows from financing activities          
Proceeds from issuance of common stock from public offering, net   35,135    - 
Proceeds from issuance of common stock and warrants from private offering   5,500    - 
Proceeds from unsecured convertible promissory notes   -    10,000 
Issuance costs on unsecured convertible promissory notes   -    (10)
Repayment of note payable   (45)   - 
Repurchases of common shares   (917)   - 
Payment of dividends   (4,546)   - 
Net cash provided by financing activities   35,127    9,990 
           
Increase in cash, cash equivalents and restricted cash   1,842    6,382 
Cash, cash equivalents and restricted cash, at the beginning of the year   6,816    434 
Cash, cash equivalents and restricted cash, at the end of the year  $8,658   $6,816 
           
Supplemental disclosures:          
Cash paid for income taxes  $-   $- 
Interest payment on the promissory notes  $1,000   $250 
           
Supplemental disclosure of non-cash investing and financing activities:          
Issuance of common shares related to business acqusition  $3,608   $- 
Right-of-use assets and lease liability recorded upon adoption of ASC 842  $-   $4,740 
Net unrealized loss, investments in marketable debt securities  $(164)  $(9)
Recognize additional goodwill related to deferred tax liability  $362   $- 

 

 

 

 

 

Non-GAAP Financial Measure and Reconciliation

(in thousands)

(unaudited)

 

In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measure we disclose are EBITDA and Adjusted EBITDA.

 

We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).

 

We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results.

 

The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):

 

   For the three months   For the years ended 
   December 31, 2021   December 31, 2020   December 31, 2021   December 31, 2020 
GAAP net income (loss) (1)  $10,589   $(978)  $6,273   $(2,125)
Interest, net   168    245    506    233 
Depreciation and amortization   1,189    113    3,233    126 
EBITDA   11,946    (620)   10,012    (1,766)
Acquisition costs (2)   -    -    674    - 
Share-based compensation expense   745    780    3,183    1,459 
Non-cash rent expense (3)   15    -    459    - 
Bad debt expense   3,750    -    3,750    - 
Adjusted EBITDA  $16,456   $160   $18,078   $(307)

 

(1) We believe that net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.

 

(2) Transaction cost related to the Nebula acquisition.

 

(3) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 prph-20220330.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prph-20220330_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 prph-20220330_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Mar. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 30, 2022
Entity File Number 000-21617
Entity Registrant Name PROPHASE LABS, INC.
Entity Central Index Key 0000868278
Entity Tax Identification Number 23-2577138
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 711 Stewart Avenue
Entity Address, Address Line Two Suite 200
Entity Address, Address Line Three G
Entity Address, City or Town arden City
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11530
City Area Code (215)
Local Phone Number 345-0919
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0005
Trading Symbol PRPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000868278 2022-03-30 2022-03-30 iso4217:USD shares iso4217:USD shares 0000868278 false 8-K 2022-03-30 PROPHASE LABS, INC. DE 000-21617 23-2577138 711 Stewart Avenue Suite 200 G arden City NY 11530 (215) 345-0919 false false false false Common Stock, par value $0.0005 PRPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm prph-20220330.xsd prph-20220330_lab.xml prph-20220330_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prph-20220330_lab.xml" ] }, "presentationLink": { "local": [ "prph-20220330_pre.xml" ] }, "schema": { "local": [ "prph-20220330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20220330", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-30to2022-03-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-30to2022-03-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-008102-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-008102-xbrl.zip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end